The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Over the last 5 years, revenue has grown at a yearly rate of 19.55%, vs industry average of 13.4%, and market share increased from 3.71% to 4.58%. The newly opened Noida hospital began operations in September 2025 and faces ramp-up challenges, though management remains optimistic about future growth with plans for further expansion including a new super specialty hospital in Guwahati.
Cyborg Score Rationale
The company has a market cap of ₹31,495 crores as of February 2026. Q3 FY26 showed revenue growth of 19.1% YoY with EBITDA margins at 25.4% (ex-Noida). However, PAT dropped 33.5% YoY due to depreciation, finance costs, and exceptional items related to the new Noida facility.
Top Insights
Strong 5-year revenue CAGR of 19.55% outpacing industry average of 13.4%, demonstrating market share gains in India's fragmented healthcare sector
Strategic expansion into Noida with 550-bed facility now operational but facing profitability headwinds; future expansion planned in Guwahati signaling growth ambitions
Market cap of ₹31,495 Cr with P/E ratio of 65.42 suggests premium valuation reflecting growth expectations and brand strength
Diverse specialty focus (cardiac, oncology, neurosciences, transplants) provides revenue diversification and positions company in high-acuity, higher-margin segments
Named Competitors
Apollo Hospitals — Multi-specialty tertiary care provider with national presence
Fortis Healthcare — Pan-India hospital network with diverse specialties
Max Healthcare — Tertiary care provider with focus on North India
Aster DM Healthcare — Multi-specialty hospital chain across India
Recent Developments
(December 2025) Q3 FY26: Revenue reached INR 11,428 million, up 19.1% YoY; EBITDA margins at 25.4% excluding Noida hospital operations
(September 2025) Medanta Noida hospital commenced operations with 550 beds; facing initial losses due to ramp-up costs
(February 2026) Management meeting with investors/analysts scheduled in Gurugram
Open the full interactive Global Health Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.